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Abstract 
Background: The aim of the study was to investigate both the inflammation-boosting 
effect and the metabolic stress induced by acute hyperglycemia secondary to 
overfeeding with excessive glucose infusion, and the effects of insulin therapy on those 
events in a rat model of sepsis. 5 
Materials and Methods: Sprague-Dawley rats underwent cecal ligation and puncture 
(CLP) or a sham operation. Pre-established continuous intravenous glucose infusion 
was initiated immediately after surgery. First, rats with CLP-inducing sepsis were 
divided into three groups on the basis of the target blood glucose (BG): high glucose 
(HG) group (overfed: >300 mg/dL), moderate glucose (MG) group (moderate 10 
hyperglycemia: 200 to 300 mg/dL), and no glucose (NG) group (100 to 150 mg/dL). 
The Sham group received the same glucose infusion as HG. Blood glucose and plasma 
interleukin (IL)-6 levels were monitored over time. All rats were sacrificed 9 hours after 
surgery to evaluate lung histology and measure hepatic total glutathione and 
malondialdehyde contents. Based on the results, the high glucose and insulin (HI) group 15 
was added to septic groups as a model of insulin therapy, in which insulin with the same 
high glucose dose as HG was administered to maintain moderate hyperglycemia. 
Results: BG in all groups remained in the pre-established target range throughout the 
experiment. Plasma IL-6 in all septic groups increased in a time-dependent manner, 
while that in the Sham group with moderate hyperglycemia hardly increased. Nine 20 
hours after CLP, plasma IL-6 in HG rose to 7407.5 ± 1987.3 pg/ml, which was three 
times higher than the other septic groups. There was no significant difference among 
MG, NG and HI, in which BG remained constant at <300 mg/dL. HG showed the worst 
consequences of lung injury and oxidative stress in the liver, which were completely 
stable in HI. 25 
Conclusion: Acute severe hyperglycemia in critical illness might excessively boost the 
existing systemic inflammatory response in a threshold-based manner. Insulin therapy 
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under overfeeding could strongly inhibit such a boosting effect and oxidative stress in 
the liver. 
 
Key Words: sepsis; hyperglycemia; inflammation; oxidative stress; metabolic stress; 
insulin 5 
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Introduction 
Since the Leuven studies, glycemic control during critical illness has been considered 
essential and effective in improving prognosis [1–3]. Sepsis is a representative critical 
illness, and many therapeutic guidelines, as typified by the Surviving Sepsis Campaign, 
stress the importance of glycemic control as a treatment for the causes of sepsis [4]. 5 
There is growing evidence of the deleterious effects of acute hyperglycemia, one of 
which is the promotion of the inflammatory cascade [5, 6]. Previous studies have shown 
that acute hyperglycemia is associated with rapidly increasing concentrations of 
circulating cytokines such as interleukin (IL)-6 in both non-stressed and critically ill 
patients [5–8]. Likewise, in vivo studies in animals have shown that acute 10 
hyperglycemia enhances cytokine production and the oxidative response within hours 
under both non-stressed conditions and stressful conditions induced by endotoxin [9, 
10]; however, these studies offer few suggestions regarding the extent to which acute 
hyperglycemia during critical illness amplifies the existing systemic inflammatory 
response. Thus, there has been no investigation in either the clinical setting or in vivo 15 
experiments to answer this important question. These considerations prompted us to 
clarify three key questions as follows. The first is whether acute hyperglycemia actually 
promotes excessive systemic inflammation in severe infection. If so, further detailed 
questions arise: (1) By how much is the systematic inflammatory response boosted?; (2) 
How much time is required before the onset of this phenomenon?; (3) What is the 20 
manner of the systemic inflammatory response boost, i.e. proportionate to blood glucose 
levels or threshold-based? The second key question is whether insulin therapy can 
inhibit such an inflammation-boosting effect caused by acute hyperglycemia. The third 
key question is whether insulin therapy also improves metabolic stress associated with 
acute hyperglycemia induced by overfeeding, such as oxidative stress [9, 11]. To 25 
examine these issues, we designed a rat model of acute hyperglycemia obtained by 
adjusting intravenous glucose loading under septic conditions induced by cecal ligation 
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and puncture (CLP). CLP is widely used as a standard model to induce sepsis in 
laboratory animals [12, 13]. This rat model is suitable to test the deleterious effects of 
acute hyperglycemia mimicking the common clinical condition of overfeeding with 
excessive glucose infusion under septic conditions in clinical settings. 
 5 
Materials and Methods 
Animals 
Thirty-five male, seven-week-old Sprague-Dawley rats (Nippon Clea, Tokyo, Japan), 
weighing approximately 300 g, were used in the experiment. The animals were 
maintained at 21 °C under 12 h light/dark cycles and allowed free access to water and 10 
standard chow for 3 to 5 days. The experimental protocols were carried out in a humane 
manner after receiving approval from the Institutional Animal Experiment Committee 
of the University of Tsukuba and in accordance with the Regulations for Animal 
Experiments of our university and the Fundamental Guidelines for Proper Conduct of 
Animal Experiments and Related Activities in Academic Research Institutions under the 15 
Jurisdiction of the Ministry of Education, Culture, Sports, Science, and Technology. 
Operative procedure 
Prior to surgery, all rats were anesthetized with an intraperitoneal injection of 
pentobarbital sodium (Somnopentyl; Kyoritsu Seiyaku Co., Tokyo, Japan) at a dose of 
40 mg/kg body weight. Under aseptic conditions, the following was performed: (1) Left 20 
carotid artery catheterization. The arterial catheter was a polyethylene tube of 0.58 mm 
inner diameter and 0.965 mm outer diameter (Becton, Dickinson and Co., Franklin 
Lakes, NJ, USA). (2) Right jugular vein catheterization in a central venous position. 
The tip of the central venous catheter was a silicone tube of 0.5 mm inner diameter and 
1.0 mm outer diameter (Fuji Systems Co., Tokyo, Japan), and the rest of the catheter 25 
was a plastic tube of the same diameter (Imamura Co., Chiba, Japan). The distal ends of 
each catheter were tunneled subcutaneously and exited in the cephalad portion of the 
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interscapular area. The catheters were fixed to the skin using a harness attached to a 
swivel assembly. (3) After catheterization, CLP was performed. Following a 3 cm 
midline incision, the cecum was exposed and ligated with a 3-0 silk suture below the 
ileocecal valve. The cecum was then punctured through both sides with an 18 gauge 
needle. After a small amount of feces had extruded from the punctured site, the cecum 5 
was placed back into the peritoneum. Sham-operated animals received catheterization 
and simple laparotomy, but not CLP. The abdominal wall and skin were closed with 2-0 
synthetic absorbable sutures (VICRYL; Ethicon, Tokyo, Japan). To ensure technical 
uniformity, all procedures including CLP were performed by only one surgeon (lead 
author of this article). Following these procedures, the rats were maintained in 10 
individual metabolic cages and were not allowed access to food or water. Immediately 
after surgery, an arterial catheter was infused with normal saline containing 0.05 U/ml 
of heparin at a rate of 0.1ml/h using infusion pumps (SP-115; JMS Co., Ltd., Tokyo, 
Japan) for catheter maintenance.  
First experimental design 15 
Rats were divided into two main groups: Groups under septic conditions induced by 
CLP and the Sham group without sepsis. Moreover, the groups under septic conditions 
were divided into three groups on the basis of the target blood glucose (BG) levels: the 
high glucose (HG) group (n = 7), in which intravenous infusion of HG at approximately 
40 mg/kg body weight/min, equivalent to 228 kcal/kg body weight/day, led to severe 20 
hyperglycemia (blood glucose >300 mg/dL); moderate glucose (MG) group (n = 7), in 
which intravenous moderate glucose infusion of approximately 25 mg/kg body 
weight/min, equivalent to 148 kcal/kg body weight/day, led to moderate hyperglycemia 
(200 to 300 mg/dL); and no glucose (NG) group (n = 7), in which normal saline was 
administered as a non-glucose solution allowed glycemic control (BG <150 mg/dL), 25 
recommended by the second edition (2008) of the Surviving Sepsis Campaign 
guidelines (100 to 150 mg/dL) [14]. The Sham group (n = 7) received the same 
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intravenous glucose infusion as the HG group (40 mg/kg body weight/min), leading to 
the development of moderate hyperglycemia (200 to 300 mg/dL). The amount of 
glucose infusion to achieve each targeted blood glucose level was determined by pilot 
studies (data not shown). Immediately after surgery, continuous intravenous 
administration of each solution using infusion pumps (SP-115; JMS Co., Ltd.) was 5 
initiated uniformly at a rate of 9 ml/kg body weight/h (approximately 2.7 ml/h) via the 
central venous catheter. In the HG, MG and Sham groups, each solution was adjusted by 
mixing two different glucose-added electrolytic solutions (Hicaliq NC-L and Hicaliq 
NC-H; TERUMO Co., Tokyo, Japan) to ensure a predetermined amount of glucose 
infusion (Table 1).  10 
Just before surgery (CLP or sham operation), and 3 and 6 hours after surgery, 0.4 ml 
blood samples were obtained, respectively, via the arterial catheter to determine blood 
glucose and plasma inflammatory cytokine levels. Nine hours after surgery, all rats were 
sacrificed to obtain tissue and blood samples in order to analyze lung histology, 
oxidative stress markers and clinical chemistry markers. The reason why the 15 
experimental period was designed for nine hours was because pilot studies revealed that 
the HG group had a mortality of over 40 percent after 12 hours (data not shown). 
Second experimental design 
The results of the first experiment indicated that plasma IL-6 did not increase 
depending on the increase in BG levels, but was likely to rise sharply when BG 20 
exceeded a certain threshold level, which may be equivalent to 300 mg/dl. To confirm 
this possibility, the high glucose and insulin (HI) group (n = 7) was added to the groups 
under septic conditions as a model of insulin therapy, in which recombinant human 
insulin (6 IU/kg/h; Eli Lilly Japan, Kobe, Japan) with the same intravenous high glucose 
infusion as the HG group (Table 1) was administered by constant intravenous infusion 25 
so as not to exceed the upper limit of moderate hyperglycemia (300 mg/dL) at 9 hours 
after CLP. According to this experimental design, all examination items were evaluated 
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in the HI group. 
Analytical Procedures 
Glucose monitoring 
Blood samples (10 μl) from the arterial catheter were analyzed using a blood glucose 
meter (FreeStyle; NIPRO, Osaka, Japan) at each measurement time point. 5 
Cytokine monitoring 
We measured blood IL-6 levels to estimate the degree of systemic inflammatory 
response because blood IL-6 levels accurately reflect the activation of cytokine cascades 
and are well correlated with the severity of sepsis [15, 16]. Blood samples (0.4 ml) from 
the arterial catheter at each measurement time point were anticoagulated with 10 
ethylenediaminetetraacetic acid (EDTA) and centrifuged to obtain plasma. Plasma 
levels of IL-6 were determined using an enzyme linked immunosorbent assay (ELISA) 
kit (R&D Systems, Minneapolis, MN, USA). 
Blood biochemistry analysis 
Blood samples (4 ml) were collected at the end of the study. Serum samples were 15 
analyzed with FUJI DRY-CHEM 3500 (FUJIFILM Co., Tokyo, Japan) to measure 
aspartate amino transferase (AST), alanine transaminase (ALT), blood urea nitrogen 
(BUN) and creatinine (CRE) levels, which roughly represent liver and renal functions. 
Oxidative stress analysis 
We analyzed the total glutathione (GSH) and malondialdehyde (MDA) content in the 20 
liver as an oxidative stress marker [11, 17]. The depletion of GSH, regarded as an 
anti-oxidant molecule, and increment of the MDA, regarded as a lipid peroxidative end 
product, are consequential findings of oxidative stress enhancement [18–20]. Liver 
tissues were collected at the end of the study, immediately frozen with liquid nitrogen, 
and kept at -80 °C until analysis. The GSH and MDA contents in the liver were 25 
determined using a colorimetric determination kit (Japan Institute for the Control of 
Aging, Nikken SEIL Co., Shizuoka, Japan). 
8 
 
Histopathological Analysis 
Right lungs were obtained at the end of the study. Lung tissue specimens were ﬁxed 
with 10% phosphate-buffered formaldehyde and then embedded in paraffin. 
Histopathological sections (4 μm) were stained with hematoxylin-eosin. Two 
pathologists blind to treatment assignment evaluated the extent of lung injury according 5 
to Murakami’s technique [21]. Brieﬂy, 24 areas of lung parenchyma were graded on a 
scale of 0–4 (0, absent and appears normal; 1, light; 2, moderate; 3, strong; 4, intense) 
for congestion, edema, inﬂammation, and hemorrhage. 
Statistics 
 All data are presented as the mean ± standard error of the mean. For comparison of 10 
more than two groups, statistical analyses were performed with one-way factorial 
analysis of variance (ANOVA). When ANOVA was found to be significant at the 95% 
confidence level, multiple comparisons between groups were made by the 
Tukey-Kramer test. For the histological study, the Kruskal-Wallis test was performed. 
Comparisons between the HG and HI groups were made by the two-sided 15 
Mann-Whitney’s U test. P <0.05 was considered significant. 
 
Results 
Data of blood biochemical examinations (Table 2) 
At the end of this experiment, some markers in the septic groups showed a higher 20 
value than those of the Sham group. There were no significant differences in serum 
levels of AST, ALT, BUN and CRE among the HG, MG and NG groups (P = 0.54, 0.63, 
0.16, 0.15, respectively). Serum levels of BUN in the HG group were higher than those 
in the HI group (P <0.01). As a result, no liver or kidney failure occurred during the 
experimental period. 25 
Blood glucose levels (Figure 1) 
Just before surgery (CLP or sham operation), there was no significant difference 
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among any of the groups. In the groups under septic conditions without insulin 
treatment (HG, MG and NG groups), BG was likely to increase depending on the 
amount of glucose infusion. In the HG group, BG remained markedly raised (severe 
hyperglycemia: >300 mg/dL) throughout the experiment, and reached 463.3 ± 48.8 
mg/dL 9 hours after CLP. The HI group, receiving the same high glucose infusion as the 5 
HG group with insulin, showed moderate hyperglycemia (200 to 300 mg/dL) from 6 to 
9 hours after CLP. Thus, BG in all groups remained in the pre-established target range 
throughout the experiment. 
Plasma interleukin-6 levels (Figure 2) 
Just before surgery, there were no significant differences among any of the groups. 10 
Plasma IL-6 in the septic groups (HG, MG, NG and HI groups) increased with time. The 
HG group with severe hyperglycemia (BG >300 mg/dL) showed a sudden rise in 
plasma IL-6 at 3 hours after CLP, and plasma IL-6 eventually rose to 7407.5 ± 1987.3 
pg/ml, which was more than three times the values measured in the other septic groups 
and significantly higher (P <0.01). On the other hand, plasma IL-6 in the Sham group 15 
with moderate hyperglycemia peaked 3 hours after the sham operation, and then 
exhibited a declining trend, which resulted in 49.1 ± 26.3 pg/ml and showed no 
significant difference between the initial value and the last value after the start of the 
experiment (P = 0.12). In the HI group with insulin therapy, a sudden increment in 
plasma IL-6 was prevented in spite of administering the same glucose infusion as the 20 
HG group. There was no significant difference among MG, NG and HI groups, in which 
BG remained constant at <300 mg/dL (P = 0.25). 
Histological examination (Figure 3, 4)  
Typical histological appearances of lung tissues accompanying septic conditions are 
shown in Figure 3. In contrast to the Sham group (Fig. 3A), lung tissues in the septic 25 
groups demonstrated an increase in both interstitial edema and inflammatory cells (Fig. 
3B, 3C, 3D, 3E). As an overview, the lung injury in the HG group appeared to be worse 
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than in the other septic groups. Figure 4 shows the quantitative result of the extent of 
lung injury in each group. Histological scores of edema and inflammation in the HG 
group were significantly higher than in MG NG, and Sham groups (P <0.01). In the HI 
group, histological scores of edema and inflammation were significantly lower than in 
the HG group (P <0.01). 5 
Total glutathione contents in the liver (Figure 5) 
Total GSH contents in the liver in the HG, MG, NG, HI and Sham groups were 1.26 ± 
0.23, 1.64 ± 0.23, 3.17 ± 0.30, 2.24 ± 0.26 and 1.86 ± 0.38 mmol/mg tissue, respectively. 
Among the septic groups without insulin treatment, total GSH content in the liver 
showed a tendency to decrease inversely with the amount of glucose infusion, and the 10 
HG group had the lowest value. In the NG group, total GSH content in the liver was 
significantly higher than in the other groups (P <0.01 versus HG and MG, P = 0.02 
versus Sham). Hepatic total GSH contents in the HI group were significantly higher 
than in the HG group, in spite of receiving the same intravenous high glucose infusion 
(P = 0.02).  15 
Malondialdehyde content in the liver (Figure 6) 
MDA contents in the liver in the HG, MG, NG, HI and Sham groups were 46.7 ± 4.1, 
40.2 ± 1.8, 35.2 ± 2.5, 39.3 ± 4.4 and 40.9 ± 3.0 mmol/mg tissue, respectively. The 
change patterns of hepatic MDA content were opposite those of hepatic total GSH 
content; however, the differences were not statistically significant (P = 0.09). 20 
 
Discussion 
In this study, we first demonstrated that acute hyperglycemia actually promotes 
excessive systemic inflammation in severe infection. In addition, the present study 
might provide new insight into two important issues; the manner of the 25 
inflammation-boosting effect caused by acute hyperglycemia, and the effects of insulin 
therapy on acute hyperglycemia under overfeeding. 
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As explained earlier, plasma IL-6 levels can be regarded as a useful index of systemic 
inflammatory response [15, 16]. BG in the NG group fluctuated between 100 to 150 
mg/dL throughout this experiment, which is comparable to the target range 
recommended by Surviving Sepsis Campaign guidelines [14]; therefore, in the NG 
group without harmful hyperglycemia, the changes in plasma IL-6 levels were 5 
considered to be purely induced by septic conditions. Thus, using the change in plasma 
IL-6 in the NG group as the base allowed us to evaluate whether plasma IL-6 changes in 
the two other septic groups (HG and MG groups) were affected by factors other than 
septic conditions, such as harmful hyperglycemia. In the HG group, severe 
hyperglycemia (>300 mg/dL) led to a sharp rise in plasma IL-6 after six hours of sepsis, 10 
which then markedly increased by 1000 pg/ml, with the result being more than three 
times that of the NG group. On the other hand, in the MG group with moderate 
hyperglycemia, plasma IL-6 fluctuated in the same manner as in the NG group, and 
there was no significant difference between the two groups. In the Sham group with 
moderate hyperglycemia under non-septic conditions, there was a slight increase in 15 
plasma IL-6, which was less than one seventieth that of the HG group. As previously 
reported, in non-stressed subjects, the increment in circulating cytokine concentrations 
induced by acute severe hyperglycemia was very small [5]. Likewise, in the Sham 
group, which was not associated with septic conditions, the increment in plasma IL-6 
was hardly promoted by moderate hyperglycemia. As might be expected, the presence 20 
of inflammation above a certain degree is a precondition when acute hyperglycemia 
strongly amplifies an inflammatory response. While HG and MG groups were 
associated with the same septic conditions, there was a major and significant difference 
in the fluctuations in plasma IL-6 between the two groups. Moreover, plasma IL-6 in the 
MG group fluctuated in the same manner as in the NG group. A notable point is that the 25 
HG group remained severely hyperglycemic, while the MG group remained moderately 
hyperglycemic. These results indicated that plasma IL-6 did not increase depending on 
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the increase in BG levels, but was likely to rise sharply when BG exceeded a certain 
threshold level, which may be equivalent to 300 mg/dl. This presumption could be 
validated by the evidence obtained from the HI group receiving the same high glucose 
dose as the HG group. In the HI group, insulin therapy could maintain moderate 
hyperglycemia and subsequently prevent a sudden increment in plasma IL-6, which 5 
allowed for maintenance of the same level as in both MG and NG groups. Here, we can 
provide an answer to our first key question as follows: acute severe hyperglycemia 
excessively boosts an existing systemic inflammatory response, such as sepsis, on a 
short-term basis (within half a day) and in a threshold-based manner. These 
experimental findings provide new insight into the deleterious effects of acute 10 
hyperglycemia in critical illness. The maintenance of BG below a certain level is 
imperative as a treatment measure to prevent excessive promotion of the inflammatory 
cascade in critical illness. 
Another point to keep in mind is that the existing systemic inflammatory response 
enhanced by acute severe hyperglycemia caused organ damage on a short-term basis. 15 
The results of histological scores regarding lung injury were consistent with the degree 
of systemic inflammatory response evaluated by plasma IL-6 levels. In the HG group 
with a marked increase in plasma IL-6, the severity of lung injury showed the worst 
findings of interstitial edema and inflammatory cell inﬁltration in both the overview 
image and histological scoring. Meanwhile, in the HI group, such harmful events were 20 
completely avoided by insulin therapy, the underlying mechanism of which might be 
blood glucose-lowering action, mainly through stimulation of skeletal muscle glucose 
uptake [22, 23]. Here, we can provide an answer to the second key question as follows: 
insulin therapy could strongly inhibit the boosting effect on the existing systemic 
inflammatory response due to acute hyperglycemia, allowing for the prevention of a 25 
cytokine storm and organ damage. 
The last key question is whether insulin therapy can improve metabolic stress 
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associated with acute hyperglycemia induced by overfeeding, namely, excessive glucose 
infusion. We used total GSH and MDA content in the liver to evaluate the state of 
oxidative stress. Not only chronic, but also acute hyperglycemia enhances oxidative 
stress under non-stress conditions [9, 11, 24]. Sepsis itself is also a powerful factor 
generating oxidative stress [18, 25]. The finding that glucose infusion increases 5 
oxidative stress depending on the applied dose is corroborated by the discovery that the 
total GSH content in the liver showed a tendency to decrease inversely with the amount 
of glucose infusion among the septic groups (HG, MG, and NG groups). Moreover, in 
the NG group receiving no glucose infusion, the hepatic total GSH content was 
maintained at a significantly higher level than in the Sham group. On the other hand, the 10 
change patterns of hepatic MDA content were opposite those of hepatic total GSH 
content because the increment of MDA reflected an increase in oxidative stress. Unlike 
in the case of GSH, the differences among all groups did not reach statistical 
significance (P = 0.09). This result might be likely to be due to the experimental period. 
The increment in hepatic MDA content should start to occur subsequent to the depletion 15 
of anti-oxidant molecules such as GSH, so the experimental period of 9 hours was too 
short for changes in hepatic MDA content to show a significant difference. From the 
above standpoint, administration of a large dose of glucose appears to have a stronger 
impact on oxidative stress in the liver than severe systemic inflammation such as sepsis, 
which means that glucose infusion promotes the enhancement of oxidative stress in the 20 
liver. In the HI group, hepatic total GSH content was significantly higher than in the HG 
group, in spite of administering the same intravenous high glucose infusion. Thus, 
insulin therapy exerts antioxidant effects in the liver; however, this benefit is achieved 
by enhancing glucose uptake into skeletal muscle cells instead of hepatocytes, which 
might put a lot of stress on muscle cells, e.g., increasing the production of reactive 25 
oxygen species and/or by-products [9]. 
In the present study, important limitations need to be addressed. We could analyze each 
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finding based on clear observations and provide unequivocal answers to three key 
questions posed in the introduction; however, the underlying mechanism of each 
observation remains to be fully elucidated. Further investigations are needed to clarify 
each mechanism. 
 5 
Conclusions 
First, the present study clarified the interaction between acute hyperglycemia under 
septic conditions and with an inflammatory response. Acute severe hyperglycemia 
might excessively boost the existing systemic inflammatory response on a short-term 
basis and in a threshold-based manner. Second, we examined the effects of insulin 10 
therapy for acute severe hyperglycemias secondary to overfeeding with excessive 
glucose infusion. Under overfed conditions, insulin therapy could strongly inhibit such a 
boosting effect on the existing systemic inflammatory response and oxidative stress in 
the liver. 
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Figure Legends 
Figure 1. Changes in blood glucose levels in each group after surgery. 
Sham: 40 mg/kg/min glucose infusion after sham operation. HG: 40 mg/kg/min glucose 
infusion after cecal ligation and puncture (CLP). MG: 25 mg/kg/min glucose infusion 
after CLP. NG: normal saline infusion after CLP. HI: 40 mg/kg/min glucose and 6 
IU/kg/h insulin infusion after CLP. Data are expressed as the mean ± SE. *P <0.05 
versus MG, NG and Sham (one way measures ANOVA and Tukey-Kramer test). †P 
<0.05 versus HG (two-sided Mann-Whitney U test). 
 
Figure 2. Changes in plasma interleukin -6 levels in each group after surgery. 
Sham: 40 mg/kg/min glucose infusion after sham operation. HG: 40 mg/kg/min glucose 
infusion after cecal ligation and puncture (CLP). MG: 25 mg/kg/min glucose infusion 
after CLP. NG: normal saline infusion after CLP. HI: 40 mg/kg/min glucose and 6 
IU/kg/h insulin infusion after CLP. Data are expressed as the mean ± SE. *P <0.05 
versus MG, NG and Sham (one way measures ANOVA and Tukey-Kramer test). †P 
<0.05 versus HG (two-sided Mann-Whitney U test). 
 
Figure 3. Typical histological appearance of lung tissue.  
(A) Lung tissue obtained from rats in Sham group (40 mg/kg/min glucose infusion after 
sham operation). (B) Lung tissue obtained from rats in HG group (40 mg/kg/min 
glucose infusion after cecal ligation and puncture). (C) Lung tissue obtained from rats in 
MG group (25 mg/kg/min glucose infusion after cecal ligation and puncture method). 
(D) Lung tissue obtained from rats in NG group (normal saline infusion after cecal 
ligation and puncture method). (E) Lung tissue obtained from rats in HI group (40 
mg/kg/min glucose and 6 IU/kg/h insulin infusion after cecal ligation and puncture). 
Sections of lung specimens were stained with hematoxylin and eosin at ×100 
magnification. 
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Figure 4. Histological scores of lung tissue. 
Sham: 40 mg/kg/min glucose infusion after sham operation. HG: 40 mg/kg/min glucose 
infusion after cecal ligation and puncture (CLP). MG: 25 mg/kg/min glucose infusion 
after CLP. NG: normal saline infusion after CLP. HI: 40 mg/kg/min glucose and 6 
IU/kg/h insulin infusion after CLP. Data are expressed as the mean ± SE. ‡P <0.05 
versus HG (Kruskal-Wallis test). †P <0.05 versus HG (two-sided Mann-Whitney U 
test). 
 
Figure 5. Total glutathione contents in the liver in each group. 
Sham: 40 mg/kg/min glucose infusion after sham operation. HG: 40 mg/kg/min glucose 
infusion after cecal ligation and puncture (CLP). MG: 25 mg/kg/min glucose infusion 
after CLP. NG: normal saline infusion after CLP. HI: 40 mg/kg/min glucose and 6 
IU/kg/h insulin infusion after CLP. Data are expressed as the mean ± SE. §P <0.05 
versus HG (one way measures ANOVA and Tukey-Kramer test). †P <0.05 versus HG 
(two-sided Mann-Whitney’s U test). 
 
Figure 6. Malondialdehyde contents in the liver in each group. 
Sham: 40 mg/kg/min glucose infusion after sham operation. HG: 40 mg/kg/min glucose 
infusion after cecal ligation and puncture (CLP). MG: 25 mg/kg/min glucose infusion 
after CLP. NG: normal saline infusion after CLP. HI: 40 mg/kg/min glucose and 6 
IU/kg/h insulin infusion after CLP. Data are expressed as the mean ± SE.
 
  
Table 1 Composition of nutrient solution in five groups 
 Sham HG MG NG HI 
Glucose (g/l) 264 264 171 0 264 
Sodium (mEq/l) 71.4 71.4 71.4 154 71.4 
Potassium (mEq/l) 42.9 42.9 42.9 0 42.9 
Insulin dose (IU/kg body weight/h) 0 0 0 0 6 
Energy intake (kcal/kg body weight/day) 228 228 148 0 228 
Sham: 40 mg/kg/min glucose infusion after sham operation. HG: 40 mg/kg/min glucose infusion after cecal ligation and puncture 
method (CLP). MG: 25 mg/kg/min glucose infusion after CLP. NG: normal saline infusion after CLP. HI: 40 mg/kg/min glucose and 6 
IU/kg/h insulin infusion after CLP. 
 
Table 1
  
Table 2 Blood biochemical examination data 
 Sham  HG  MG  NG  HI   
AST 99.5 ± 7.0  124.0 ± 9.8  129.7 ± 11.6  113.5 ± 9.3  109.7 ± 6.3  N.S. 
ALT 31.6 ± 2.6  49.6 ± 4.2 ¶ 48.4 ± 4.3 ¶ 44.3 ± 3.8  47.0 ± 3.3   
BUN 3.0 ± 0.3  9.5 ± 1.6 ¶ 7.9 ± 1.1 ¶ 11.6 ± 1.1 ¶ 5.5 ± 1.0 †  
CRE 0.14 ± 0.02  0.29 ± 0.06 ¶ 0.20 ± 0.02  0.19 ± 0.01  0.1 ± 0.0 †  
Sham: 40 mg/kg/min glucose infusion after sham operation. HG: 40 mg/kg/min glucose infusion after cecal ligation and puncture 
method (CLP). MG: 25 mg/kg/min glucose infusion after CLP. NG: normal saline infusion after CLP. HI: 40 mg/kg/min glucose and 6 
IU/kg/h insulin infusion after CLP. AST: aspartate amino transferase, ALT: alanine transaminase, BUN: blood urea nitrogen, CRE: 
creatinine. Numbers for blood biochemical measurements are the mean ± standard error. N.S.: no significance, ¶: P <0.05 versus Sham 
(one way measures ANOVA and Tukey-Kramer test), †: P <0.05 versus HG (two-sided Mann-Whitney U test). 
Table 2
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